title: Suppression of acute hepatic injury by a synthetic prostacyclin agonist through hepatocyte growth factor expression.
abstract: Previous studies have demonstrated that mice disrupted with the cyclooxygenase-2 gene showed much more severe liver damage compared with wild-type mice after liver injury, and prostaglandins (PGs) such as PGE(1/2) and PGI(2) have decreased hepatic injury, but the mechanisms by which prostaglandins exhibit protective action on the liver have yet to be addressed. In the present study, we investigated the mechanism of the protective action of PGI(2) using the synthetic IP receptor agonist ONO-1301. In primary cultures of hepatocytes and nonparenchymal liver cells, ONO-1301 did not show protective action directly on hepatocytes, whereas it stimulated expression of hepatocyte growth factor (HGF) in nonparenchymal liver cells. In mice, peroral administration of ONO-1301 increased hepatic gene expression and protein levels of HGF. Injections of CCl4 induced acute liver injury in mice, but the onset of acute liver injury was strongly suppressed by administration of ONO-1301. The increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) by CCl4 were suppressed by 10 mg/kg ONO-1301 to 39.4 and 33.6%, respectively. When neutralizing antibody against HGF was administered with ONO-1301 and CCl4, the decreases by ONO-1301 in serum ALT and AST, apoptotic liver cells, and expansion of necrotic areas in liver tissue were strongly reversed by neutralization of endogenous HGF. These results indicate that ONO-1301 increases expression of HGF and that hepatoprotective action of ONO-1301 in CCl4-induced liver injury may be attributable to its activity to induce expression of HGF, at least in part. The potential for involvement of HGF-Met-mediated signaling in the hepatotrophic action of endogenous prostaglandins generated by injury-dependent cyclooxygenase-2 induction is considerable.
authors.affiliation: Division of Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa Univ., Kakuma, Kanazawa, Japan.
authors.forename: Qing
authors.initials: Q
authors.lastname: Xu
authors.forename: Mizuho
authors.initials: M
authors.lastname: Nakayama
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Katsuya
authors.initials: K
authors.lastname: Sakai
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nakamura
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sakai
authors.forename: Kunio
authors.initials: K
authors.lastname: Matsumoto
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002478:Cells, Cultured; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism / Q000517:prevention & control*; D054407:Chemokine CCL4 / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D017228:Hepatocyte Growth Factor / Q000235:genetics / Q000378:metabolism*; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D011725:Pyridines / Q000494:pharmacology*; D011982:Receptors, Prostaglandin / Q000819:agonists*
chemical_list: D054407:Chemokine CCL4; D011725:Pyridines; D011982:Receptors, Prostaglandin; C105488:ONO 1301; D017228:Hepatocyte Growth Factor; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase